Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates. Is now the time to buy Amphastar Pharmaceuticals? Find out in our full research report. Amphastar Pharmaceuticals (AMPH) Q3 CY2025 Highlights: Revenue: $191.8 million vs analyst estimates of $184.5 million (flat year on year, 4% beat) Adjust ...